Bristol-Myers Squibb's flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunotherapy ...
Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...
The heart is a pump, and the blood goes round, and round, and round all the time. And why does it do that? Why can't it just have a rest? Well, the blood has to be kept moving around all the time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback